Clinical trial
Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1
NCT02122952 · Novartis Gene Therapies, Industry · Completed
Key facts
| NCT number | NCT02122952 |
|---|---|
| Title | Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 |
| Official title | Phase I Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS-101 |
| Lead sponsor | Novartis Gene Therapies, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Spinal Muscular Atrophy 1 |
| Intervention type | Biological |
| Interventions | AVXS-101 |
| Enrollment | 15 |
| Start date | May 5, 2014 |
| Primary completion | Dec 15, 2017 |
| Completion | Dec 15, 2017 |
| First posted | Apr 25, 2014 |
| Last update posted | Sep 15, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: